HGH Fragment 176-191 holds no approved status of any kind in the United States, and that single absence drives every other legal question about it. Under the Federal Food, Drug, and Cosmetic Act a substance is a drug by its intended use, so a product marketed for fat loss without an approved application is an unapproved new drug the moment it moves in interstate commerce. The distinction that carries the most practical weight is between unscheduled and lawful: the fragment is the first without being the second.
HGH Fragment 176-191 holds no FDA approval for any indication, satisfies none of the three section 503A compounding tests, and is unscheduled under the Controlled Substances Act while remaining an unapproved new drug that cannot lawfully be marketed.
Marketing copy that calls this peptide clinically studied is usually accurate and legally beside the point. The regulatory record it gestures at belongs mostly to AOD-9604, a stabilized analogue of the same carboxyl-terminal region of human growth hormone, which reached a randomized placebo-controlled Phase IIb obesity trial running roughly twenty-four weeks and failed to separate from placebo on its primary weight-loss endpoint. Neither compound holds an approved application, and the line between studied and approved is the one with legal consequences attached.
| Regulatory record | HGH Fragment 176-191 | AOD-9604 |
|---|---|---|
| Controlled human testing | None on record | Phase IIb, roughly 24 weeks |
| Primary endpoint result | Not applicable | No separation from placebo |
| FDA approval | None | None; obesity program discontinued |
| Drugs@FDA and Orange Book | Absent | Absent |
Neither HGH Fragment 176-191 nor its analogue AOD-9604 appears in Drugs@FDA or the Orange Book, and AOD-9604's Phase IIb obesity trial of roughly twenty-four weeks failed to separate from placebo before the program was discontinued.
Federal drug law does not run from a list of banned substances, which is where most of the confusion on this question starts. Section 201(g) of the Federal Food, Drug, and Cosmetic Act defines a drug functionally, by intended use, and intended use is proven with objective evidence: website copy, dosing charts, testimonials, before-and-after imagery, even the circumstances of sale. A vial sold with subcutaneous injection instructions for body-fat reduction is a drug as a matter of law, whatever the label reads.
Under sections 201(g), 505(a), and 301(d) of the Federal Food, Drug, and Cosmetic Act the absence of an approved application is itself the violation, with misbranding under section 502 and adulteration under section 501 attaching as independent theories.
Compounding is the pathway most often assumed to be open, and for this peptide it is shut. Section 503A exempts a traditional compounded preparation from approval, adequate directions for use, and current good manufacturing practice only when the bulk drug substance passes at least one of three tests, and this fragment passes none of them. A prescription from a fully licensed physician does not repair the defect, because the problem sits in the starting material rather than in the prescriber's authority.
HGH Fragment 176-191 satisfies none of section 503A's three bulk drug substance tests, so a compounded preparation of it never carries the statutory exemption and remains an unapproved new drug regardless of the prescriber's license.
It is not scheduled, and that fact answers a much narrower question than online discussion usually assumes. Scheduling turns on abuse potential, dependence liability, and accepted medical use, a framework built around psychoactive small molecules, while the Anabolic Steroid Control Act's definition reaches only drugs chemically and pharmacologically related to testosterone. A sixteen-residue fragment of a one-hundred-ninety-one-amino-acid protein sits outside both, which says nothing at all about whether it may lawfully be sold.
| Dimension | Controlled Substances Act | Drug approval law |
|---|---|---|
| Enforcing agency | Drug Enforcement Administration | Food and Drug Administration |
| Question it asks | Abuse potential, dependence, accepted medical use | Approval, labeling, manufacturing |
| Status of the fragment | Absent from Schedules I through V | Unapproved new drug |
| Effect on lawful sale | None | Marketing and shipment prohibited |
HGH Fragment 176-191 appears nowhere in Schedules I through V and falls outside the Anabolic Steroid Control Act's testosterone-related definition, yet it remains an unapproved new drug that cannot lawfully be marketed or shipped.
This is the one genuinely unresolved legal question in the subject, and it is better described honestly than settled by assertion. Congress placed an unusual criminal provision at 21 U.S.C. 333(e), a felony carrying up to five years in prison and up to ten where a person under eighteen is involved, for knowingly distributing or possessing with intent to distribute human growth hormone for human uses other than those authorized by the Secretary. Whether a sixteen-amino-acid fragment with none of the growth-promoting, insulin-antagonizing, or IGF-1-raising activity that defines the hormone counts as human growth hormone under that text has never been resolved by a published appellate decision.
21 U.S.C. 333(e) criminalizes distributing or possessing with intent to distribute human growth hormone for unauthorized human use, carrying up to five years in prison, and no published appellate decision resolves whether its undefined term analogue reaches a sixteen-residue fragment.
The supplement route fails on several independent grounds, which is why FDA has been able to act against peptide products labeled as supplements without much difficulty. The Dietary Supplement Health and Education Act lists what qualifies as a dietary ingredient, and a synthetic sixteen-residue peptide with no history of use as a food component fits none of those categories under any reading.
HGH Fragment 176-191 fits none of the dietary ingredient categories in the Dietary Supplement Health and Education Act and is separately caught by the drug preclusion clause, so supplement or cosmetic labeling adds misbranding and false-labeling exposure rather than legitimizing a sale.
Research use only is a real regulatory category, and almost nothing sold online under that banner sits inside it. Its legitimate meaning comes from the device and diagnostic world, where a product genuinely confined to the laboratory research phase of development may be distributed without clearance. FDA and the courts read intended use from the totality of objective evidence, so the phrase describes a product's actual stream of use rather than suspending the law that would otherwise apply.
Research use only labeling is a marketing convention rather than a legal safe harbor, and in fraud-based counts the disclaimer has cut against defendants by showing awareness that the sale was improper.
The border is the one chokepoint where inspection is routine rather than complaint-driven, which is why an unapproved peptide most often meets the government there. Section 801(a) of the Federal Food, Drug, and Cosmetic Act lets FDA refuse admission to any article that appears from examination or otherwise to be an unapproved new drug, misbranded, or adulterated, and appears is a deliberately low standard that shifts the burden onto the importer.
Section 801(a) permits FDA to refuse admission to any article that merely appears to be an unapproved new drug, and the personal importation policy is enforcement discretion in a regulatory procedures manual that has never covered performance or body composition products.
Exposure is spread very unevenly across the supply chain, and collapsing the tiers into one is the common analytical error. Sellers absorb nearly all of the federal weight, clinics meet state boards and insurance exclusions, and the realistic downside for a personal-quantity purchaser is a destroyed parcel.
Sellers face injunction, seizure, and felony exposure while an individual purchaser's realistic worst case is a refused and destroyed import, and the Federal Trade Commission polices weight-loss claims under a separate substantiation standard regardless of whether FDA acts.
For anyone inside an anti-doping system the answer is both clearer and stricter than the general legal one. HGH Fragment 176-191 is named on the World Anti-Doping Agency Prohibited List by name, as hGH 176-191, added alongside AOD-9604 as an example of a growth hormone fragment in the 2018 list and still there.
hGH 176-191 has been named alongside AOD-9604 under section S2 of the World Anti-Doping Agency Prohibited List since the 2018 list, prohibited at all times both in and out of competition and enforced on strict liability.
Setting the two side by side shows what approval actually buys, and produces one counterintuitive result. Recombinant human growth hormone is approved as somatropin across a defined set of indications with FDA-reviewed labeling, current good manufacturing practice and lot release testing, a traceable licensed supply chain, and mandatory adverse event reporting, none of which exists for the fragment. Growth hormone is also one of the very few drugs whose off-label distribution is effectively criminalized, so in that narrow respect the approved product is more tightly controlled than the unapproved one, which cannot lawfully be sold or compounded at all.
| Dimension | Approved somatropin | HGH Fragment 176-191 |
|---|---|---|
| Approved indications | Pediatric and adult GHD, Turner syndrome, Prader-Willi, others | None |
| Labeling and manufacturing | FDA-reviewed labeling, cGMP with lot release testing | No approved labeling, no release testing |
| Off-label distribution | Effectively criminalized by 21 U.S.C. 333(e) | No lawful sales channel at all |
| Permitted claims | Consistent with labeling, risk information required | Every efficacy claim evidences a violation |
Approved somatropin carries FDA-reviewed labeling, lot release testing, a licensed supply chain, and mandatory adverse event reporting across its approved indications, while HGH Fragment 176-191 has none of that infrastructure and no lawful route to market short of an investigational new drug exemption and approval.
Educational use only. This article describes what the published scientific and clinical literature reports about HGH Fragment 176-191. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
